Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ARRY-300, MEK inhibitor · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| ARRY-300 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| ARRY-300, MEK inhibitor; oral | DRUG | single dose, escalating |
| Placebo | DRUG | matching placebo |
Key Inclusion Criteria: * Healthy male or female (females must be of non-childbearing potential) between the ages of 18 and 50 years, inclusive. * Body mass index (BMI) of 18 kg/m2 to 35 kg/m2; and a total body weight \> 50 kg (110 lbs) and \< 113 kg (280 lbs). * Additional criteria exist. Key Exc...
ARRY-300 is an investigational small molecule MEK inhibitor being studied in healthy volunteers. It is not approved for any indication and is in early clinical development. A Phase 1 trial evaluated its safety in healthy subjects, but it is not being developed for a specific disease at this time.
ARRY-300 targets MEK, a kinase enzyme involved in cell signaling pathways. By inhibiting MEK, it may interfere with cellular proliferation and survival. This mechanism is being explored in early clinical research, though the drug is currently studied only in healthy subjects.
Pfizer, Inc. (NYSE: PFE) is developing ARRY-300. The company is conducting clinical research on this investigational MEK inhibitor, which is currently in Phase 1 development.
ARRY-300 is in Phase 1 clinical development. It is an investigational drug, not yet approved by regulatory authorities. The Phase 1 trial has been completed, and the drug remains in early-stage research.
ARRY-300 has one completed Phase 1 trial, NCT00828165, titled 'A Safety Study of ARRY-300 in Healthy Subjects.' This randomized, double-blind, placebo-controlled study enrolled 12 participants in the United States and evaluated the drug's safety in healthy adults aged 18 and older.